Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

Abstract: A panel system includes a chassis holding one or more tray arrangements, which are each configured to receive one or more cassettes at two or more bays. The tray arrangements and cassettes cooperate to define a cassette sensor arrangement and a port occupancy sensor arrangement having separate interface points. The cassette sensor arrangement may include electronic memory storing physical layer information about the cassette. All active components of the port occupancy sensor arrangement are disposed on the tray while the electronic memories of the cassette sensor arrangement are stored on the cassettes.

Abstract: The invention relates to imidazopyridines of Formula (I) and pharmaceutically acceptable salts thereof, wherein R0 to R5 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

Abstract: An articulating tire valve install-removal tool and related methods for use. The articulating tire valve install-removal tool has a body comprising an outer perimeter, an inner recess, a threaded member, a linkage, and a contact member. The articulating tire valve install-removal tool components are connected to each other and secured within the body so one or more components can rotate around one or more axes. Together these components facilitate in the valve being installed and removed perpendicular or generally perpendicular to the valve hole on the wheel. The articulating tire valve stem tool includes a linkage assembly that is attached to the body to facilitate in ensuring the valve is installed and removed with the valve perpendicular to the valve hole in the wheel rim.

Abstract: Methods and systems described herein relate to the creation of a digital repository of artificial intelligence models that allows users to determine their individual fairness metric. More specifically, the methods and systems provide this digital repository by storing it on a blockchain network and tracking any changes made to the model and/or its fairness metric.

Abstract: Disclosed embodiments include systems and methods for providing a secure physical storage system. The system may receive a request to register a first physical storage box from an entity including location information and security information. The request can be validated by comparing the security information to a predetermined security threshold. The location information associated with the first physical storage box can be recorded to a blockchain. The first registration information can be received from a first user device. The first physical storage box can be assigned to the first user device and a first identity token associated with the first physical storage box. The assignment information associated with the first physical storage box can be recorded to the blockchain. A first identity token can be received from the first user device. Instructions can be transmitted to the first physical storage box to transition from a locked to an unlocked state.

Abstract: The presence of a plug connector with a port is detected through a detection circuit activated by a port shutter. Transitioning the port shutter between the closed (i.e., blocking the port) position and the open position actuates and deactuates the detection circuit.

Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

Abstract: 4-Alkoxypyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4-alkoxypyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).

Abstract: The present invention relates to antibodies comprising Fc variants and their uses. The Fc variants exhibit reduced or undetectable binding to Fc receptors, and reduced or undetectable effector functions. These variants are beneficial for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector functions induced by antibodies.

Abstract: Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer’s disease, diabetes, viral infections, and osteoarthritis).

Abstract: Aspects of this disclosure relate generally to the use of biomaterials for the in vivo generation of CAR expressing cells. In some embodiments, the biomaterials comprise one or more of a cell recruitment composition, a viral vector, and/or a cell activation agent.

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.

Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Abstract: Pyrrolo[2,3-b]pyridine compound for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,3-b]pyridine compound or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).

Abstract: To provide a space-saving bipolar plate for a fuel cell comprising an anode plate and a cathode plate, anode gas channels and cathode gas channels lead from main gas ports on opposite sides into an active area and are distributed across the width of said area such that they are subsequently diverted towards an opposite distribution area, and the coolant channels branch in the distribution area and, after branching, are diverted towards the anode gas channels and towards the cathode gas channels and, in each region of overlap with the anode gas channels and the cathode gas channels, are diverted collectively such that the coolant channels lead, together with the anode gas channels and the cathode gas channels, into the active area with no overlap and alternatingly with said anode gas channels and cathode gas channels.

Abstract: 7H-Pyrrolo[2,3-d]pyrimidine compound for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 7H-pyrrolo[2,3-d]pyrimidine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).

Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.